Clinical Cancer Research, Vol 4, Issue 10 2439-2445, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer

RE Howells, CW Redman, KK Dhar, P Sarhanis, C Musgrove, PW Jones, J Alldersea, AA Fryer, PR Hoban and RC Strange
Department of Obstetrics and Gynaecology, North Staffordshire Hospital, Stoke-on-Trent, England.

Epithelial ovarian cancer is generally associated with a poor outcome, although the mechanisms that determine survival and progression-free interval (PFI) are unclear. Data from ovarian tumors showing associations between (a) null genotypes at the glutathione S-transferase GSTM1 and GSTT1 loci and expression of p53 protein and (b) outcome and expression of p53 suggest that polymorphism at these loci is a factor determining outcome. Accordingly, we have studied the association between the GSTM1 null and GSTT1 null genotypes and survival and PFI in 148 women with epithelial ovarian cancer. Although we did not find an association between individual genotypes and outcome, women with both GSTM1 null and GSTT1 null genotypes demonstrated poorer survival (P = 0.001) and reduced PFI (P = 0.003). Thus, no cases with both these genotypes survived past 42 months postdiagnosis. In contrast, 43% of the women without this combination survived beyond this time. Because response to chemotherapy is a major factor determining outcome in ovarian cancer, we also examined the data for associations between the glutathione S-transferase genotypes and response to such treatment. Thus, in 78 patients treated with chemotherapy, the combination of GSTM1 null and GSTT1 null was associated with unresponsiveness to primary chemotherapy (P = 0.004); none of the eight patients with both these genotypes responded, compared with 38 of 70 (54%) of patients with other genotype combinations. The effect of the combination of genotypes on survival and PFI was lost in a multivariate model that included response to chemotherapy as a confounding factor. This suggests that the combination of GSTM1 null/GSTT1 null is associated with outcome because of its influence on response to chemotherapy. These preliminary findings may provide a basis for the selection of patients for treatment with chemotherapeutic agents.

This article has been cited by other articles:

				P. Yang, J. O. Ebbert, Z. Sun, and R. M. Weinshilboum Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review J. Clin. Oncol., April 10, 2006; 24(11): 1761 - 1769. [Abstract] [Full Text] [PDF]

				R. Rajagopal, M. Deakin, A.S. Fawole, J.B. Elder, J. Elder, V. Smith, R.C. Strange, and A.A. Fryer Glutathione S-transferase T1 polymorphisms are associated with outcome in colorectal cancer Carcinogenesis, December 1, 2005; 26(12): 2157 - 2163. [Abstract] [Full Text] [PDF]

				P. Barnette, R. Scholl, M. Blandford, L. Ballard, A. Tsodikov, J. Magee, S. Williams, M. Robertson, F. Ali-Osman, R. Lemons, et al. High-Throughput Detection of Glutathione S-Transferase Polymorphic Alleles in a Pediatric Cancer Population Cancer Epidemiol. Biomarkers Prev., February 1, 2004; 13(2): 304 - 313. [Abstract] [Full Text] [PDF]

				F. Sata, H. Yamada, T. Kondo, Y. Gong, S. Tozaki, G. Kobashi, E.H. Kato, S. Fujimoto, and R. Kishi Glutathione S-transferase M1 and T1 polymorphisms and the risk of recurrent pregnancy loss Mol. Hum. Reprod., March 1, 2003; 9(3): 165 - 169. [Abstract] [Full Text] [PDF]

				M. T. Voso, F. D'Alo', R. Putzulu, L. Mele, A. Scardocci, P. Chiusolo, R. Latagliata, F. Lo-Coco, S. Rutella, L. Pagano, et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia Blood, September 26, 2002; 100(8): 2703 - 2707. [Abstract] [Full Text] [PDF]

				C. B. Ambrosone, C. Sweeney, B. F. Coles, P. A. Thompson, G. Y. McClure, S. Korourian, M. Y. Fares, A. Stone, F. F. Kadlubar, and L. F. Hutchins Polymorphisms in Glutathione S-Transferases (GSTM1 and GSTT1) and Survival after Treatment for Breast Cancer Cancer Res., October 1, 2001; 61(19): 7130 - 7135. [Abstract] [Full Text] [PDF]

				S. M. Davies, L. L. Robison, J. D. Buckley, T. Tjoa, W. G. Woods, G. A. Radloff, J. A. Ross, and J. P. Perentesis Glutathione S-Transferase Polymorphisms and Outcome of Chemotherapy in Childhood Acute Myeloid Leukemia J. Clin. Oncol., March 1, 2001; 19(5): 1279 - 1287. [Abstract] [Full Text] [PDF]

				A. B. Spurdle, P. M. Webb, D. M. Purdie, X. Chen, A. Green, and G. Chenevix-Trench Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype Carcinogenesis, January 1, 2001; 22(1): 67 - 72. [Abstract] [Full Text] [PDF]

				T. A. Lallas, S. K. McClain, M. S. Shahin, and R. E. Buller The Glutathione S-Transferase M1 Genotype in Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 587 - 590. [Abstract] [Full Text]